Wedbush Securities’s Corcept Therapeutics CORT Stock Holding History

Wedbush Securities’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,109	Closed	-$302K	–	1185
2025 Q2	$302K	Buy	+4,109	New	+$298K	0.01%	833
2015 Q2	–	Sell	-20,000	Closed	-$112K	–	738
2015 Q1	$112K	Hold	20,000	–	–	0.02%	653
2014 Q4	$60K	Hold	20,000	–	–	0.01%	669
2014 Q3	$54K	Sell	20,000 -1,000	-5%	-$2.65K	0.01%	660
2014 Q2	$59K	Buy	21,000 +10,000	+91%	+$29.5K	0.01%	632
2014 Q1	$48K	Hold	11,000	–	–	0.01%	607
2013 Q4	$35K	Sell	11,000 -5,000	-31%	-$10.1K	0.01%	571
2013 Q3	$25K	Hold	16,000	–	–	0.01%	567
2013 Q2	$28K	Buy	+16,000	New	+$28.8K	0.01%	537

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Wedbush Securities's CORT Position: Q3 2025 in Review

Wedbush Securities sold out of Corcept Therapeutics (CORT) in Q3 2025, closing a stake of 4,109 shares — an estimated $302K sold.

Wedbush Securities first reported a position in CORT in Q2 2013 and held it in 9 quarters. The position peaked at $302K in Q2 2025. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

Wedbush Securities reported no remaining Corcept Therapeutics position as of Q3 2025 after selling out during the quarter.
Wedbush Securities sold 4,109 Corcept Therapeutics shares in Q3 2025, an estimated $302K.
Wedbush Securities first reported a position in Corcept Therapeutics in Q2 2013 and held it in 9 quarters.
Wedbush Securities's Corcept Therapeutics position peaked at $302K in Q2 2025.
429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on Wedbush Securities's 13F filing for Q3 2025, filed 6 Nov 2025.